Related Experiment Videos

Transforming growth factor-beta signal transduction in epithelial cells

J Yue1, K M Mulder

  • 1Department of Pharmacology, MC H078, Pennsylvania State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA.

Pharmacology & Therapeutics
|November 15, 2001
PubMed

Insights

Transforming growth factor-beta (TGF-beta) inhibits normal cell growth but can be bypassed by tumors. Understanding TGF-beta signaling in epithelial cells is crucial for developing new cancer therapies.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Oncology

Background:

  • Transforming growth factor-beta (TGF-beta) is a potent inhibitor of normal cell growth, including epithelial cells.
  • TGF-beta's growth inhibitory effects are relevant to epithelial-derived tumors like breast and colon carcinomas.
  • Tumor cells often develop resistance to TGF-beta due to signaling pathway defects, and TGF-beta may promote tumor invasiveness.

Purpose of the Study:

  • To review the TGF-beta signal transduction pathways in epithelial cells.
  • To focus on recent advances in the Smad and Ras/MAPK pathways downstream of TGF-beta receptors.
  • To summarize TGF-beta's signal transduction mechanisms and cell cycle effects.

Main Methods:

  • Literature review of TGF-beta signaling pathways.
  • Focus on Smad and Ras/MAPK signaling cascades.
  • Analysis of TGF-beta's effects on cell cycle regulation.

Main Results:

  • Two primary TGF-beta signaling cascades identified: Smad and Ras/MAPK pathways.
  • These pathways mediate TGF-beta's diverse cellular effects.
  • Understanding these pathways is key to overcoming tumor resistance.

Conclusions:

  • TGF-beta signaling pathways, particularly Smad and Ras/MAPK, are critical in normal epithelial cells.
  • Elucidating these pathways is essential for developing targeted anticancer therapeutics.
  • This review provides a comprehensive summary of TGF-beta signaling and its cell cycle effects.

Related Concept Videos